Probi’s largest clinical trial confirms the immune enhancing impact of Probi Defendum® and sheds new light on the mechanism


Probi’s largest clinical trial ever, focused on probiotic immune health, has recently been completed. The study included over 900 subjects and was carried out over a period of 3 winter seasons. The randomized, double-blind, placebo-controlled trial confirms the strong clinical immune enhancing effect of Probi Defendum®. The study proves Probi Defendum® to protect against recurrent colds in addition to shedding some light on the mechanism of action behind the effect.

Probi Defendum®, a probiotic immune concept based on the combination of Probi’s patented probiotic strains, Lactobacillus plantarum HEAL9 and Lactobacillus paracasei 8700:2 has in previous clinical studies shown strong immune enhancing effects.

The new clinical study included 900 participants over three winter seasons. Probi Defendum® was given once daily for 12 weeks and common colds were used as a model to examine effects on the immune system.

The results from the study show that Probi Defendum® significantly decreases recurrent common colds. In addition, in subjects not experiencing a common cold, an activation of the immune system was apparent already after two weeks of intake of Probi Defendum®. Moreover, there was a reduced overall severity of common cold symptoms with Probi Defendum® compared to placebo during the first season.

“We are proud to conclude that our largest clinical trial so far has successfully confirmed earlier clinical results. Interestingly, in subjects that did not experience any viral infection during the study period, there was an activation of the immune system measured already after 2 weeks of Probi Defendum® intake, indicating an alert and resilient immune system.” says Peter Nählstedt, CEO of Probi AB.

Immune health is the second largest health area for probiotics and Probi Defendum® is presently sold in several geographical markets. The new clinical data will strengthen the Probi Defendum® concept even further and support existing products in the consumer market. It will also create opportunities for new launches by new and existing customers aiming to extend a probiotic gastro position into new health areas, both within the Consumer Healthcare and the Functional Food segment.

To learn more about the new clinical results and Probi Defendum®please join the upcoming webinar presented by Irini Lazou Ahrén, PhD, Senior Scientist at Probi. Register at


Peter Nählstedt, CEO, Probi, tel +46 46 286 89 23, e-mail:
Linda Neckmar, Vice President EMEA & APAC, Probi, tel +46 46 286 89 71, e-mail:

**Please note, Thumbay Group, Gulf Medical University, and HEALTH magazine are not liable nor responsible for the facts, figures, and overall content of the press releases on our portal.

Related Articles